FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma

October 18, 2017 – The U.S. Food and Drug Administration today approved axicabtagene ciloleucel, a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Axicabtagene ciloleucel, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma … (leggi tutto)